外用雷帕霉素治疗结节性硬化症面部血管纤维瘤疗效显著：优化治疗方案 - Suppr

Suppr

超能文献

Dramatic improvement of facial angiofibromas in tuberous sclerosis with topical rapamycin: optimizing a treatment protocol.

作者信息

DeKlotz Cynthia M C, Ogram Alicia E, Singh Saurabh, Dronavalli Sridhar, MacGregor Jennifer L

出版信息

Arch Dermatol. 2011 Sep;147(9):1116-7. doi: 10.1001/archdermatol.2011.254.

DOI:10.1001/archdermatol.2011.254

PMID:21931059

Abstract

摘要

相似文献

Dramatic improvement of facial angiofibromas in tuberous sclerosis with topical rapamycin: optimizing a treatment protocol.

Arch Dermatol. 2011 Sep;147(9):1116-7. doi: 10.1001/archdermatol.2011.254.

Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis.

Arch Dermatol. 2010 Jul;146(7):715-8. doi: 10.1001/archdermatol.2010.125.

[Topical sirolimus 0.4% formulation for treatment of facial angiofibromas].

Farm Hosp. 2012 Sep-Oct;36(5):433-4. doi: 10.1016/j.farma.2011.09.006. Epub 2012 Jul 31.

[Facial angiofibromas associated to tuberous sclerosis treated with topical sirolimus].

Ugeskr Laeger. 2013 Oct 21;175(43):2569-70.

A novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex.

J Child Neurol. 2013 Jul;28(7):933-6. doi: 10.1177/0883073813488664. Epub 2013 May 16.

Topical 0.2% rapamycin to treat facial angiofibromas and hypomelanotic macules in tuberous sclerosis.

Actas Dermosifiliogr. 2014 Oct;105(8):802-3. doi: 10.1016/j.ad.2013.09.013. Epub 2013 Dec 17.

Treatment of facial angiofibromas with topical application of oral rapamycin solution (1mgmL(-1) ) in two patients with tuberous sclerosis.

Br J Dermatol. 2011 Oct;165(4):922-3. doi: 10.1111/j.1365-2133.2011.10476.x.

Comparative Effects of Topical 0.2% Sirolimus for Angiofibromas in Adults and Pediatric Patients with Tuberous Sclerosis Complex.

Dermatology. 2018;234(1-2):13-22. doi: 10.1159/000489089. Epub 2018 Jun 20.

Tuberous Sclerosis Complex in 29 Children: Clinical and Genetic Analysis and Facial Angiofibroma Responses to Topical Sirolimus.

Pediatr Dermatol. 2017 Sep;34(5):572-577. doi: 10.1111/pde.13204. Epub 2017 Aug 2.

A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity.

Br J Dermatol. 2011 Oct;165(4):912-6. doi: 10.1111/j.1365-2133.2011.10471.x.

引用本文的文献

Efficacy and Safety of Topical Mechanistic Target of Rapamycin Inhibitors for Facial Angiofibromas in Patients with Tuberous Sclerosis Complex: A Systematic Review and Network Meta-Analysis.

Biomedicines. 2022 Mar 31;10(4):826. doi: 10.3390/biomedicines10040826.

Comparison of the In Vitro and Ex Vivo Permeation of Existing Topical Formulations Used in the Treatment of Facial Angiofibroma and Characterization of the Variations Observed.

Pharmaceutics. 2020 Nov 7;12(11):1060. doi: 10.3390/pharmaceutics12111060.

Safety and Efficacy of the Sirolimus Gel for TSC Patients With Facial Skin Lesions in a Long-Term, Open-Label, Extension, Uncontrolled Clinical Trial.

Dermatol Ther (Heidelb). 2020 Aug;10(4):635-650. doi: 10.1007/s13555-020-00387-7. Epub 2020 May 8.

Long-term stability of 0.1% rapamycin hydrophilic gel in the treatment of facial angiofibromas.

Eur J Hosp Pharm. 2020 Mar;27(e1):e48-e52. doi: 10.1136/ejhpharm-2018-001695. Epub 2018 Nov 10.

Long-Term Exposure and Safety of a Novel Topical Rapamycin Cream for the Treatment of Facial Angiofibromas in Tuberous Sclerosis Complex: Results From a Single-Center, Open-Label Trial.

Child Neurol Open. 2019 Apr 14;6:2329048X19835047. doi: 10.1177/2329048X19835047. eCollection 2019.

Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial.

JAMA Dermatol. 2018 Jul 1;154(7):773-780. doi: 10.1001/jamadermatol.2018.0464.

Sirolimus Gel Treatment vs Placebo for Facial Angiofibromas in Patients With Tuberous Sclerosis Complex: A Randomized Clinical Trial.

JAMA Dermatol. 2018 Jul 1;154(7):781-788. doi: 10.1001/jamadermatol.2018.1408.

The neural crest lineage as a driver of disease heterogeneity in Tuberous Sclerosis Complex and Lymphangioleiomyomatosis.

Front Cell Dev Biol. 2014 Nov 25;2:69. doi: 10.3389/fcell.2014.00069. eCollection 2014.

Topical rapamycin as a treatment for fibrofolliculomas in Birt-Hogg-Dubé syndrome: a double-blind placebo-controlled randomized split-face trial.

PLoS One. 2014 Jun 9;9(6):e99071. doi: 10.1371/journal.pone.0099071. eCollection 2014.

Challenges in the management of a case of tuberous sclerosis.

Ind Psychiatry J. 2012 Jul;21(2):148-51. doi: 10.4103/0972-6748.119635.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验